Prostate Cancer

The role of CD38 within prostate cancer progression must be further explored, along with CD38-targeting in patients with high-risk disease.

Germline variation could play a role in racial disparities related to prostate cancer risk, with individuals of African descent having a higher mean genetic risk score compared with men of European ancestry.

Dr Neal Shore explains the clinical implications of PSMA PET scans in advanced prostate cancer.

Scott T. Tagawa, MD, MS, FACP, discusses integration of prostate-specific membrane antigen [PSMA] positron emission tomography [PET] imaging into community practice to help identify potential candidates for PSMA-targeted radioligand therapy.

Scott T. Tagawa, MD, MS, FACP, reviews implications for treating prostate-specific membrane antigen (PSMA) -positive advanced prostate cancer with lutetium-177–PSMA-617 based on results of the phase III VISION study and additional trials in the pipeline.

Wassim Abida, MD, PhD, discusses the clinical significance of the results from the phase 2 TRITON2 trial in metastatic castration-resistant prostate cancer.

Michael J. Morris, MD, discusses ongoing research efforts with 177Lu-PSMA-617 in prostate cancer.

An overview of the diagnostic and therapeutic applications of PSMA in prostate cancer is presented.

Insights generated from several trials presented during the 2021 ASCO Annual Meeting in renal cell carcinoma illustrate the importance of evaluating checkpoint inhibitors in earlier stages of disease, quality of life, and long-term outcomes, and other data that point to 2 potential new standards of care in prostate cancer.

The net effect of the Oncotype DX Genomic Prostate Score in patients with favorable-risk prostate cancer was to move away from active surveillance, altering the understanding of how prognostic molecular assays that generate probabilities of poor outcome can impact treatment decisions in diverse populations.

Christopher Pieczonka, MD, discusses the rationale to evaluate sabizabulin in men with metastatic castration-resistant prostate cancer in the phase 3 VERACITY trial.

A discussion of phenotypic and genotypic biomarkers found in prostate cancer and their implications.

Neal Shore, MD, discusses the complexity of prostrate cancer and factors to consider when determining management strategies.

An overview of safety and efficacy data presented at ASCO 2021 from the phase III VISION study of lutetium-177-PSMA-617 in patients with metastatic castration-resistant prostate cancer.

A discussion on the sensitivity and specificity of an emerging imaging modality, PSMA PET, in advanced prostate cancer.

Dr Scott T. Tagawa describes what prostate-specific membrane antigen (PSMA) is and explains its evolving role as a diagnostic, prognostic and therapeutic target in patients with advanced prostate cancer.

Leanne Burnham, PhD, discusses the need to close the gap in health disparities in prostate cancer.

A new prognostic tool, the nomogram, has demonstrated the ability to predict outcomes following treatment with lutetium-177 prostate-specific membrane antigen in patients with metastatic castration-resistant prostate cancer, and could potentially be used to inform future trial designs and clinical decisions.

Yung Lyou, MD, PhD, discusses emerging biomarkers in prostate cancer.

Ipatasertib plus abiraterone acetate and prednisone demonstrated a significant improvement in radiographic progression-free survival vs placebo plus abiraterone in patients with metastatic castration-resistant prostate cancer with PTEN loss, according to findings from the ongoing phase 3 IPATential150 trial now published in The Lancet.

Yung Lyou, MD, PhD, discusses optimal sequencing with apalutamide in prostate cancer.

Neal Shore, MD, FACS, discusses the impact of crossover from placebo to darolutamide on OS benefit in patients with nmCRPC enrolled to the ARAMIS trial, and next steps for the androgen receptor inhibitor.

Leanne Burnham, PhD, discusses health disparities in prostate cancer.

The addition of a focal boost to the intraprostatic lesion was found to improve biochemical disease-free survival in patients undergoing treatment with external beam radiotherapy for localized intermediate- and high-risk prostate cancer.

Evangelia Sereti, MSc, PhD, discusses the unmet need addressed with the addition of NOV202 to olaparib in BRCA1/2-mutated prostate cancer.